Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Recruiting 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Thoracic 1

Conditions

Carcinoma, Non-Small-Cell Lung 31Carcinoma, Hepatocellular 18Neoplasms 13Neoplasm Metastasis 13Melanoma 13Esophageal Neoplasms 12Nasopharyngeal Carcinoma 10Head and Neck Neoplasms 9Esophageal Squamous Cell Carcinoma 9Colorectal Neoplasms 9Squamous Cell Carcinoma of Head and Neck 8Breast Neoplasms 8Triple Negative Breast Neoplasms 7Stomach Neoplasms 7Recurrence 7Pancreatic Neoplasms 7Rectal Neoplasms 6Carcinoma, Renal Cell 6Biliary Tract Neoplasms 6Lung Neoplasms 5Small Cell Lung Carcinoma 4Sarcoma 4Ovarian Neoplasms 4Locally Advanced Rectal Cancer 4Colonic Neoplasms 4Advanced NSCLC 4Urinary Bladder Neoplasms 3Prostatic Neoplasms 3Liver Neoplasms 3Leukemia, Myeloid, Acute 3

Interventions

Pemetrexed 1Immune Checkpoint Inhibitors 1Drug Therapy 1Carboplatin 1CP protocol 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Interventional × First-line Advanced NSCLC Patients × Immune Checkpoint Inhibitors × Clear all
NCT07171606 2025-12-18

A Phase II Study of SSGJ-706 Monotherapy and Combination Therapy in Advanced Non-Small Cell Lung Cancer(NSCLC) Patients

Shenyang Sunshine Pharmaceutical Co., LTD.

Phase 2 Recruiting
240 enrolled
Thoracic

First-line Advanced NSCLC Patients

Data powered by HemOnc (CC BY 4.0) Colophon âš¡